首页> 美国卫生研究院文献>Journal of Radiation Research >Long-term outcomes of induction chemotherapy followed by chemoradiotherapy using volumetric-modulated arc therapy as an organ preservation approach in patients with stage IVA-B oropharyngeal or hypopharyngeal cancers
【2h】

Long-term outcomes of induction chemotherapy followed by chemoradiotherapy using volumetric-modulated arc therapy as an organ preservation approach in patients with stage IVA-B oropharyngeal or hypopharyngeal cancers

机译:IVA-B期口咽或下咽癌患者的诱导化疗及放化疗采用容积调制弧光疗法作为器官保存方法的长期结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The present study aimed to analyze treatment outcomes after induction chemotherapy followed by chemoradiotherapy (CRT) using volumetric-modulated arc therapy (VMAT) in patients with stage IVA-B oropharyngeal cancer (OPC) or hypopharyngeal cancer (HPC), with long-term observation, including examination of larynx preservation. A total of 60 patients with stage IVA-B OPC or HPC, who underwent induction TPF chemotherapy (a combination regimen consisting of docetaxel, cisplatin, and 5-fluorouracil) followed by CRT using VMAT were analyzed. Overall survival (OS), progression-free survival (PFS), laryngoesophageal dysfunction-free survival (LEDFS), and locoregional control (LRC) were calculated and compared. Univariate and multivariate analyses were performed to determine statistical differences in OS and LEDFS. The median follow-up period at the time of evaluation was 61 months. Twenty-six (43%) patients had OPC and 34 (57%) had HPC. The 5-year OS, PFS, LEDFS, and LRC rates were 57%, 52%, 52%, and 68%, respectively. Response to TPF therapy was the only significant predictive factor of OS and LEDFS in multivariate analyses. Regarding long-term toxicities, grade ≥ 2 late toxicities accounted for 15%. No patients experienced grade ≥ 3 xerostomia, and 5% of all patients developed grade 3 dysphagia. With long-term observation, the OS, PFS, and LEDFS rates were relatively good, and the incidence of late toxicities was low. TPF followed by CRT using VMAT was feasible and more effective in those who responded to induction chemotherapy.
机译:本研究旨在分析患有IVA-B期口咽癌(OPC)或下咽癌(HPC)的患者在诱导化疗后进行放疗,然后采用容积调制弧光治疗(VMAT)进行放化疗(CRT),并进行长期观察,包括检查喉头的保存情况。分析了总共60例IVA-B OPC或HPC分期的患者,这些患者接受了VTP诱导TPF化疗(多西他赛,顺铂和5-氟尿嘧啶的联合治疗),然后进行了CRT。计算并比较了总生存期(OS),无进展生存期(PFS),无喉咽食管功能障碍生存期(LEDFS)和局部控制(LRC)。进行单变量和多变量分析以确定OS和LEDFS的统计差异。评估时的中位随访期为61个月。 26例(43%)患者患有OPC,34例(57%)患者患有HPC。 5年OS,PFS,LEDFS和LRC比率分别为57%,52%,52%和68%。在多变量分析中,对TPF治疗的反应是OS和LEDFS的唯一重要预测因素。就长期毒性而言,≥2级晚期毒性占15%。没有患者经历3级以上的口干症,所有患者中有5%发生3级吞咽困难。长期观察,OS,PFS和LEDFS率相对较高,后期毒性发生率较低。在对诱导化疗有反应的患者中,TPF联合CRT使用VMAT是可行且更有效的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号